Robert Goldman

7.0k total citations · 2 hit papers
100 papers, 5.4k citations indexed

About

Robert Goldman is a scholar working on Psychiatry and Mental health, Clinical Psychology and Cognitive Neuroscience. According to data from OpenAlex, Robert Goldman has authored 100 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Psychiatry and Mental health, 22 papers in Clinical Psychology and 22 papers in Cognitive Neuroscience. Recurrent topics in Robert Goldman's work include Schizophrenia research and treatment (46 papers), Attention Deficit Hyperactivity Disorder (23 papers) and Bipolar Disorder and Treatment (21 papers). Robert Goldman is often cited by papers focused on Schizophrenia research and treatment (46 papers), Attention Deficit Hyperactivity Disorder (23 papers) and Bipolar Disorder and Treatment (21 papers). Robert Goldman collaborates with scholars based in United States, Germany and Japan. Robert Goldman's co-authors include Robert M. Bilder, Jeffrey A. Lieberman, Delbert G. Robinson, Brian Sheitman, Miranda Chakos, Margaret G. Woerner, Stephen Geisler, David Mayerhoff, A. Koreen and Jose Ma. J. Alvir and has published in prestigious journals such as New England Journal of Medicine, American Journal of Psychiatry and Stroke.

In The Last Decade

Robert Goldman

99 papers receiving 5.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder

1999 1.0k citations Robert M. Bilder, Robert Goldman et al. profile →
A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

2020 204 citations Kenneth S. Koblan, Justine Kent et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert Goldman	3.9k	1.4k	1.2k	1.0k	685	100	5.4k
M F Green	2.9k 0.8×	1.5k 1.1×	790 0.7×	983 1.0×	500 0.7×	13	4.0k
Jean‐Pierre Lindenmayer	5.2k 1.3×	1.1k 0.8×	1.7k 1.4×	1.5k 1.5×	656 1.0×	134	6.9k
Ofer Agid	4.0k 1.0×	1.1k 0.8×	1.2k 1.1×	1.1k 1.1×	875 1.3×	135	5.9k
Miranda Chakos	6.1k 1.6×	1.4k 1.0×	1.7k 1.5×	1.5k 1.5×	941 1.4×	62	7.7k
Sonia Dollfus	3.0k 0.8×	1.5k 1.1×	721 0.6×	790 0.8×	435 0.6×	187	4.6k
Thomas Wobrock	2.5k 0.6×	1.5k 1.1×	862 0.7×	519 0.5×	529 0.8×	125	4.9k
S. Charles Schulz	2.9k 0.7×	1.6k 1.2×	1.7k 1.4×	571 0.6×	520 0.8×	158	5.2k
Brian Toone	4.2k 1.1×	2.2k 1.6×	1.0k 0.9×	720 0.7×	837 1.2×	125	6.8k
István Bitter	3.7k 1.0×	1.5k 1.1×	975 0.8×	481 0.5×	376 0.5×	156	5.1k
Larry Alphs	3.8k 1.0×	584 0.4×	1.1k 0.9×	937 0.9×	586 0.9×	174	5.2k

Countries citing papers authored by Robert Goldman

Since Specialization

Citations

This map shows the geographic impact of Robert Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Goldman more than expected).

Fields of papers citing papers by Robert Goldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Goldman. The network helps show where Robert Goldman may publish in the future.

Co-authorship network of co-authors of Robert Goldman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Goldman. A scholar is included among the top collaborators of Robert Goldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Goldman. Robert Goldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tocco, Michael, et al.. (2024). Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies. Annals of General Psychiatry. 23(1). 26–26. 1 indexed citations

Correll, Christoph U., et al.. (2022). Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. European Psychiatry. 65(1). 1–35. 8 indexed citations

DelBello, Melissa P., et al.. (2021). Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. Journal of Child and Adolescent Psychopharmacology. 31(7). 494–503. 7 indexed citations

Correll, Christoph U., Kenneth S. Koblan, Seth C. Hopkins, et al.. (2021). Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. Schizophrenia. 7(1). 63–63. 61 indexed citations

Koblan, Kenneth S., Seth C. Hopkins, Justine Kent, et al.. (2020). 138 Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia. CNS Spectrums. 25(2). 287–288. 6 indexed citations

McElroy, Susan L., James I. Hudson, Carlos M. Grilo, et al.. (2020). Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder. The Journal of Clinical Psychiatry. 81(5). 16 indexed citations

Findling, Robert L., Lenard A. Adler, Thomas Spencer, et al.. (2019). Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial. Journal of Child and Adolescent Psychopharmacology. 29(2). 80–89. 29 indexed citations

Goldman, Robert, Antony Loebel, Josephine Cucchiaro, Ling Deng, & Robert L. Findling. (2017). Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. Journal of Child and Adolescent Psychopharmacology. 27(6). 516–525. 40 indexed citations

Loebel, Antony, Robert Silva, Robert Goldman, et al.. (2016). Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia. The Journal of Clinical Psychiatry. 77(12). 1672–1680. 31 indexed citations

10.

Loebel, Antony, Matthew Brams, Robert Goldman, et al.. (2015). Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. Journal of Autism and Developmental Disorders. 46(4). 1153–1163. 64 indexed citations

11.

Ehmann, Thomas S., Robert Goldman, Jodi Yager, Yikang Xu, & G. William MacEwan. (2007). Self-reported cognitive and everyday functioning in persons with psychosis: the Patient Perception of Functioning Scale. Comprehensive Psychiatry. 48(6). 597–604. 9 indexed citations

12.

Sheitman, Brian, Michael G. Murray, Jennifer Snyder, et al.. (2000). IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. Schizophrenia Research. 46(2-3). 203–207. 24 indexed citations

13.

Szeszko, Philip R., Robert M. Bilder, Todd Lencz, et al.. (2000). Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia. Schizophrenia Research. 43(2-3). 97–108. 85 indexed citations

14.

Axelrod, Bradley N., Robert Goldman, John L. Woodard, & Larry Alphs. (1994). Factor structure of the negative symptom assessment. Psychiatry Research. 52(2). 173–179. 25 indexed citations

15.

Axelrod, Bradley N., Robert Goldman, & Larry Alphs. (1993). Validation of the 16-item negative symptom assessment. Journal of Psychiatric Research. 27(3). 253–258. 93 indexed citations

16.

Goldman, Robert, et al.. (1993). Neuropsychological Prediction of Treatment Efficacy and One-Year Outcome in Schizophrenia. Psychopathology. 26(3-4). 122–126. 50 indexed citations

17.

Tandon, Rajiv, Saulo C. M. Ribeiro, J.R. DeQuardo, et al.. (1993). Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication. Biological Psychiatry. 34(7). 495–497. 35 indexed citations

18.

Taylor, Stephan F., et al.. (1992). Neuropsychological function and REM sleep in schizophrenic patients. Biological Psychiatry. 32(6). 529–538. 17 indexed citations

19.

Goldman, Robert, Steven Finkbeiner, & Stephen J Smith. (1991). Endothelin induces a sustained rise in intracellular calcium in hippocampal astrocytes. Neuroscience Letters. 123(1). 4–8. 46 indexed citations

20.

Tandon, Rajiv, et al.. (1991). Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome. Biological Psychiatry. 29(10). 953–964. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact